Small Airway Function of Fluticasone/Formoterol (Flutiform®) and Fluticasone/Salmeterol

Exclusion Criteria

• •1. Patients who have experienced life-threatening asthma within 12 months prior to screening or respiratory infection within 4 weeks prior to screening, or patients who have experienced any emergency visit or hospitalization due to acute asthma symptoms within 4 weeks prior to screening
• •2. Patients who have diagnosed as clinically significant disease or non- reversible pulmonary disease or patients who currently have active pulmonary disease (eg. COPD, cystic fibrosis, bronchiectasis, active tuberculosis)
• •3. Patients who have diagnosed as laryngitis, chronic sinusitis, infectious rhinitis or allergic rhinitis within 4 weeks prior to screening, or patients who have had any symptoms of acute exacerbation or purulent discharge by the disease above within 2 weeks prior to screening
• •4. Current smoker or past smoker defined as below:
• •* Current smoker: smoking history within 12 months prior to screening
• •* Past smoker: smoking amount ≥10 pack year\*
• •* Pack year (PY) calculation: average amount of smoking per day (pack) x duration of smoking (year)
• •5. Patients who currently are pregnant or lactating
• •6. Patient who had taken systemic corticosteroid within 4 weeks prior to screening
• •7. Patients who had taken omalizumab within 24 weeks prior to screening
• •8. Patients who had taken the following medications within 1 week prior to screening:
• •* potent CYP3A inhibitors
• •* β-blockers
• •* monoamine oxidase inhibitor
• •* TCA (tricyclic antidepressants)
• •* quinidine-type anti arrhythmic
• •* Leukotriene anatagonist
• •* Astemizole
• •9. Patients who are participating or going to participate in any interventional clinical trials
• •10. QT interval prolongation in ECG result at screening
• •11. Patients with hypersensitive to investigational products or to any component of the drug
• •12. Patients who are judged difficult to participate in this investigation by the investigator